Key Points
- CEO Alexander Cumbo sold 48,913 shares on Feb. 4 at an average of $6.44 for ~$314,999.72, reducing his position by ~18.05% to 222,018 shares valued at about $1.43M.
- Several other senior insiders (CFO, COO, CTO, director and additional executives) also reported recent sales at $6.44, a pattern that increases supply pressure and may weigh on investor sentiment.
- Solid Biosciences (SLDB) trades near $6.50 with a market cap around $508M and a 1‑year range of $2.41–$7.37, while analysts show a "Moderate Buy" consensus and an average price target of $14.70.
Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) Director Ilan Ganot sold 7,205 shares of the company's stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $6.44, for a total transaction of $46,400.20. Following the completion of the transaction, the director owned 25,271 shares of the company's stock, valued at $162,745.24. This represents a 22.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Ilan Ganot also recently made the following trade(s):
- On Wednesday, January 28th, Ilan Ganot sold 191 shares of Solid Biosciences stock. The stock was sold at an average price of $6.59, for a total value of $1,258.69.
- On Monday, January 5th, Ilan Ganot sold 1,053 shares of Solid Biosciences stock. The shares were sold at an average price of $5.43, for a total value of $5,717.79.
Solid Biosciences Stock Up 4.7%
NASDAQ:SLDB opened at $6.52 on Friday. Solid Biosciences Inc. has a 52-week low of $2.41 and a 52-week high of $7.37. The stock's 50 day moving average price is $5.84 and its 200 day moving average price is $5.72. The company has a market capitalization of $507.97 million, a PE ratio of -2.62 and a beta of 2.67.
Wall Street Analysts Forecast Growth
SLDB has been the topic of several research reports. Wall Street Zen downgraded shares of Solid Biosciences from a "hold" rating to a "sell" rating in a research report on Sunday, October 19th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Solid Biosciences in a research note on Thursday, January 22nd. Citigroup restated a "market outperform" rating on shares of Solid Biosciences in a research report on Wednesday, December 17th. Barclays set a $9.00 price objective on Solid Biosciences and gave the stock an "overweight" rating in a research report on Tuesday, November 4th. Finally, Chardan Capital reissued a "buy" rating and issued a $15.00 target price on shares of Solid Biosciences in a report on Tuesday, November 4th. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $14.70.
View Our Latest Stock Analysis on Solid Biosciences
Institutional Investors Weigh In On Solid Biosciences
A number of institutional investors have recently added to or reduced their stakes in the business. Legal & General Group Plc raised its stake in shares of Solid Biosciences by 208.6% during the 2nd quarter. Legal & General Group Plc now owns 6,011 shares of the company's stock worth $29,000 after buying an additional 4,063 shares in the last quarter. Ameritas Investment Partners Inc. grew its holdings in Solid Biosciences by 205.5% during the second quarter. Ameritas Investment Partners Inc. now owns 6,740 shares of the company's stock worth $33,000 after acquiring an additional 4,534 shares during the period. Creative Planning acquired a new position in Solid Biosciences during the second quarter worth $57,000. Russell Investments Group Ltd. raised its position in Solid Biosciences by 142.0% in the third quarter. Russell Investments Group Ltd. now owns 10,211 shares of the company's stock worth $63,000 after acquiring an additional 5,991 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey lifted its holdings in Solid Biosciences by 233.8% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 15,113 shares of the company's stock valued at $74,000 after acquiring an additional 10,585 shares during the period. Hedge funds and other institutional investors own 81.46% of the company's stock.
Key Stories Impacting Solid Biosciences
Here are the key news stories impacting Solid Biosciences this week:
- Positive Sentiment: Company will present at the Guggenheim Emerging Outlook: Biotech Summit (CEO Bo Cumbo presenting Feb 12) — this gives Solid (SLDB) direct exposure to institutional investors and can support a rally if management provides encouraging clinical, regulatory, or financing updates. Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
- Neutral Sentiment: Trading context: SLDB is trading above recent moving averages with volume notably above its average — this suggests heightened interest but does not by itself indicate direction until drivers (presentation vs. insider sales) dominate.
- Negative Sentiment: CEO Alexander (Alex) Cumbo sold 48,913 shares at an average $6.44 (≈$315k); his holding fell ~18.1% — a large CEO sale can be read negatively by investors even if for personal reasons. CEO Sale SEC Filing
- Negative Sentiment: CFO Kevin Tan sold 14,783 shares at $6.44 (~$95k); his position fell ~13.6% — another senior officer reduction that may weigh on sentiment. CFO Sale SEC Filing
- Negative Sentiment: COO David T. Howton sold 18,894 shares at $6.44 (~$122k); ownership declined ~16.2%. COO Sale SEC Filing
- Negative Sentiment: CTO Paul Herzich sold 10,905 shares at $6.44 (~$70k); holding fell ~13.6%. CTO Sale SEC Filing
- Negative Sentiment: Other insiders — director Ilan Ganot (7,205 shares), insider Jessie Hanrahan (12,348 shares), and Gabriel Brooks (12,616 shares) — each sold at $6.44, reducing holdings by double-digit percentages; collectively these sales increase supply pressure and raise investor questions about insider confidence. Director/Insider Sales SEC Filings
Solid Biosciences Company Profile
(
Get Free Report)
Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company's primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.
Solid's lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
